Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study (Q33394281)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q42834766)
(Q53140836)
(Q40001639)
(Q87712102)
(Q28421846)
(Q89228014)
(Q88032966)
(Q87769541)
(Q117224712)
(Q88034786)
(Q114300414)
(Q117224736)
(Q117224737)
(Q114413074)
(Q117224739)
(Q89987696)
(P304) 263-272
(P433) 3
(P478) 12
(P577) Monday, February 21, 2011
(P921) (Q6934595)
(P1433) (Q13747613)
(P1476) "Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study" (language: en)
(P2093) Edie Weller
Meghan Bagshaw
Renee Leduc
Philippe Armand
Akari Dollard
Diane Warren
Tiffany Poon
(P2860) (Q34362643)
(Q36478461)
(Q79255677)
(Q46923172)
(Q36986667)
(Q35692250)
(Q29615120)
(Q40702649)
(Q35914722)
(Q40524119)
(Q33362103)
(Q40623520)
(Q40361501)
(Q40205312)
(Q40328451)
(Q34124937)
(Q39827794)
(Q33366976)
(Q29618608)
(Q34549410)
(Q33285239)
(Q42921022)
(Q33391803)
(Q33389111)
(Q34604658)
(Q37110578)
(Q34374071)
(Q37624179)
other details
description scientific article

External Links